ONDINE BIOMEDICAL
INC.
("Ondine
Biomedical", "Ondine", or the "Company")
Ondine starts first UK health
economics study
The York Health Economic
Consortium will undertake the first UK health economic analysis of
Ondine's Steriwave light-activated antimicrobial to reduce Surgical
Site Infections
Ondine Biomedical Inc. (LON:OBI),
Mid Yorkshire Teaching NHS Trust, and Health Innovation Yorkshire
and Humber are partnering with the York Health Economics Consortium
(YHEC) to evaluate the use of Ondine's light-activated
antimicrobial, Steriwave®, to reduce the incidence of surgical site
infections (SSIs).
SSIs are one of the most common
healthcare-associated infections (HAIs) and affect one in every 20
patients who undergo a surgical procedure in the NHS. SSIs can cost
up to £100,000 per patient, and the overall cost of HAIs to NHS
England is over £2 billion a year. These costs are expected to rise
as growing rates of antimicrobial resistance (AMR) make the current
standard of care - the antibiotic mupirocin - less
effective.
Steriwave uses a proprietary
photosensitizer, which is activated by a specific wavelength of red
light, to eliminate infection-causing pathogens in the nose. The
nose is a reservoir for pathogens like Staphylococcus aureus and
MRSA which are known to cause SSIs. Steriwave eliminates these
pathogens, including superbugs, in a painless five-minute treatment
and prevents them from spreading and causing infections.
Importantly, unlike today's antibiotics, the use of Steriwave does
not trigger antimicrobial resistance.
The health economic analysis is
being undertaken by YHEC, an internationally renowned provider of
health economics evaluations, and will supplement the ongoing
Steriwave pilot at Mid Yorkshire Teaching NHS Trust, which involves
500 elective hip and knee surgery patients over a period of six
months. The findings will be used to support adoption of Steriwave
across the NHS.
Dr Stuart Bond, Consultant
Antimicrobial Pharmacist and Director of Innovation at Mid
Yorkshire Teaching NHS Trust, commented: "We are very pleased to be
partnering with Ondine and the YHEC on this economic analysis to
support the promising results of the Steriwave pilot we have seen
so far. The data from the health economic analysis will support the
results of our pilot, and we hope to be able to share these later
this year."
Helen Hoyland, Head of Health
Innovation Yorkshire & Humber's Office of Life Sciences
portfolio, said: "Health Innovation Yorkshire and Humber (formerly
the Academic Health Science Network for the region) is pleased to
be supporting this evaluation. We are commissioned by the Office of
Life Sciences to support real-world evidence generation. We will
work with the innovators and the Trust to publish the evaluation
data, and then subsequently look to support further opportunities
for the spread and adoption of Steriwave, working alongside the
West Yorkshire Innovation Hub".
Steriwave is also being used in
major hospitals across Canada, including Vancouver General Hospital
(VGH), The Ottawa Hospital (TOH), and the Mazankowski Alberta Heart
Institute. Research recently published by VGH in the Canadian
Journal of Surgery showed that the use of Steriwave in patients
undergoing spine surgery resulted in a 66.5% reduction in
post-surgical infection rates and $2.5 million in annual
savings.[i] No serious
adverse events have ever been reported from Steriwave
treatment.
**ENDS**
Ondine Biomedical
Inc.
|
|
Carolyn Cross, CEO
|
+001 (604) 665 0555
|
|
|
Singer Capital Markets (Nominated Adviser and Joint
Broker)
|
|
Aubrey Powell, Asha Chotai, Sam
Butcher
|
+44 (0)20 7496 3000
|
|
|
RBC
Capital Markets (Joint Broker)
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20 7653 4000
|
|
|
Vane Percy & Roberts (Media Contact)
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77 1000 5910
|
About York Economics Consortium
York Health Economics Consortium
(YHEC) is a health economics consulting company owned by the
University of York. It provides a range of services, including
economic modelling, literature searching, systematic reviews,
network meta-analyses, patient-reported outcomes, service review
and applied research and training to the NHS and the pharmaceutical
and healthcare industries. YHEC also carries out work for a range
of clients outside the health sector, including Local Authorities
and the voluntary sector. Current clients include: the National
Institute for Health and Care Excellence (NICE), NHS England, a
range of local NHS trusts and several large multinational
pharmaceutical, device, digital health and nutrition
companies.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian
life science company innovating in the field of light-activated
antimicrobial therapies (also known as 'photodisinfection'). Ondine
has a pipeline of investigational products, based on its
proprietary photodisinfection platform, in various stages of
development. Ondine's nasal
photodisinfection system has a CE mark in Europe and the UK and is
approved in Canada and several other countries under the name
Steriwave®. In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track
status by the FDA and is currently undergoing clinical trials for
regulatory approval. Products beyond nasal photodisinfection
include therapies for a variety of medical indications such as
chronic sinusitis, ventilator-associated pneumonia, burns, and
other indications.
About Steriwave®
Ondine's Steriwave Nasal
Photodisinfection System is a patented
technology using a proprietary light-activated antimicrobial
(photosensitizer) to destroy pathogens. The photodisinfection
treatment is carried out by a trained healthcare professional and
is an easy-to-use, painless, two-step process. The
photosensitizer is applied to each nostril using a nasal swab,
followed by illumination of the area with a specific wavelength of
red light for less than five minutes. The light activates the
photosensitizer, causing an oxidative burst that is lethal to all
types of pathogens. A key benefit of this approach, unlike with
antibiotics, is that pathogens do not develop resistance to the
therapy.
Nasal decolonization with
antibiotics is already standard practice in many hospitals prior to
surgery, as pathogens in a patient's nasal cavities are a major
cause of healthcare-associated infections, including surgical site
infections (SSIs). Nasal decolonization is recommended in the 2016
WHO Global guidelines for the prevention of
SSIs,[ii] and the
Society for Healthcare Epidemiology of America (SHEA) guidelines,
published in May 2023, recommend nasal decolonization for major
surgical procedures.[iii]
However, there is a growing need to reduce traditional antibiotic
use as resistance rates have been reported as high as
81%.[iv]